ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of "Buy" from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has been given an average recommendation of "Buy" by the nine brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $78.88.

Several brokerages have recently commented on ANIP. Guggenheim reiterated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Wall Street Zen lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Truist Financial lifted their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research report on Monday, April 21st. Finally, HC Wainwright began coverage on ANI Pharmaceuticals in a research report on Thursday, July 10th. They issued a "buy" rating and a $84.00 target price for the company.

Insider Activity at ANI Pharmaceuticals

In related news, insider Christopher Mutz sold 4,000 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider owned 107,317 shares in the company, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total value of $52,921.67. Following the transaction, the senior vice president owned 89,897 shares of the company's stock, valued at $5,400,112.79. This trade represents a 0.97% decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,681 shares of company stock worth $345,222 in the last 90 days. 11.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its position in ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock worth $55,437,000 after acquiring an additional 473,097 shares during the period. Global Alpha Capital Management Ltd. boosted its position in ANI Pharmaceuticals by 17.8% during the 1st quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company's stock worth $49,248,000 after acquiring an additional 111,040 shares during the period. Dimensional Fund Advisors LP boosted its position in ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after acquiring an additional 30,420 shares during the period. Deep Track Capital LP boosted its position in ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock worth $35,879,000 after acquiring an additional 144,214 shares during the period. Finally, William Blair Investment Management LLC raised its stake in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock worth $26,826,000 after buying an additional 10,440 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Up 4.1%

ANIP stock traded up $2.60 during midday trading on Tuesday, hitting $66.60. 571,065 shares of the company's stock were exchanged, compared to its average volume of 318,321. The company has a current ratio of 2.66, a quick ratio of 1.98 and a debt-to-equity ratio of 1.46. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $77.00. The firm has a 50 day moving average price of $62.95 and a 200-day moving average price of $62.48. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -52.44 and a beta of 0.57.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. The company had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. ANI Pharmaceuticals's revenue for the quarter was up 43.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.82 EPS. On average, analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.